|Awarded On||February 19, 2020|
|Title||GD2 Expression and Response to Chemoimmunotherapy in Neuroblastoma|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||Texas Tech University Health Sciences Center|
|Principal Investigator/Program Director||Charles Reynolds|
|Cancer Sites||Brain and Other Nervous System|
*Pending contract negotiation
High-risk neuroblastoma (NB) is a lethal childhood malignancy treated with an antibody called dinutuximab. Dinutuximab binds to a molecule found on neuroblastoma cells called GD2 and results in killing the tumor cells. About 1/2 of NB patients will relapse after initial therapy, and relapse is often treated with cancer chemotherapy drugs temozolomide (TMZ) + irinotecan (IRN) + dinutuximab. We have shown that dinutuximab can enhance the killing of NB tumors grown in special mice (i.e. patient-derived xenografts =PDXs) to TMZ + IRN. We will show that dinutuximab enhances activity of TMZ + IRN against tumors with high binding of dinutuximab (high GD2) but not those with low dinutuximab binding ...